Platelet Indices in Patients Undergoing Primary PCI and Its Prognostic Value
NCT ID: NCT04290949
Last Updated: 2020-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2020-02-20
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Impact of PMI in Stable CAD Undergoing PCI
NCT04239404
The Impact Of Platelet Function on 1-year Outcome in Complex PCI Patients
NCT03353779
Kitasato PCI Registry
NCT05308329
Imaging and Physiologic Evaluation of Coronary Artery Disease
NCT05124249
Influence Of Incomplete Revascularization on Long-Term Outcomes After Primary Percutaneous Coronary Intervention (PPCI)
NCT04332250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ACS include ST- elevation Myocardial Infarction (STEMI), non ST-Elevation Myocardial Infarction (NSTEMI) and Unstable Angina (UA) (2).
ACS characterized by plaque rupture and acute thrombosis formation in the coronary arteries (3)
platelet morphology and function have vital roles in the pathogenesis of many diseases related to coagulation, thrombosis, inflammation, and endothelial dysfunction (4)
Platelets play a crucial role in thrombotic episodes, its activation is acritical factor in the creation and evolution of atherothrombosis. (5)
Not only platelets are essential for the thrombotic vascular occlusion at the ruptured atherosclerotic plaque but also they contribute to the obstruction and impairment of coronary micro circulation (6).
Risk stratification plays a crucial role in the management of patients with ACS (7).
Patients estimated to be at higher risk may be managed with earlier and more aggressive treatment, whereas those with lower risk may be managed with less intensive treatment (8).
Many biomarkers have been evaluated, and various scores have been created for risk stratification of ACS patients (9)
Mean platelet volume (MPV) has been proposed as a primary marker for platelet activation, as larger sized platelets have been associated with higher pro-thrombotic risk, and its measurement is easy and time effective (10-14)
* So It may elevate in patients with ACS and its role, It could be a useful bio marker of risk of stratification (15)
* Platelet Distribution Width (PDW) measured on admission is a cheap and generally available biomarker which allows for predicting the development of heart failure in patients with ACS after PCI (16)
showed that an increased level of PDW was related to the severity of CAD in patients with ACS (17).
Numerous studies support the association of Mean platelet volume (MPV) with adverse cardiac outcomes as restenosis stent thrombosis in patients with ACS (19-24) al.2011
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Previous revascularization procedure
3. Any history of bleeding diathesis
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ishraq Hosny Abd El-Hameed Hassan
Critical Care Unit, Internal Medicine Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alaa El din Abd El Moniem, Professor
Role: STUDY_DIRECTOR
Critical Care Unit, Internal Medicine Department
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Platelet indices in acute MI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.